The round was led by General Catalyst with participation from Breyer Capital, Morningside Ventures and Sound Ventures and existing investors Jim Manzi, chairman, Thermo Fisher Scientific Inc. and former chairman, president and CEO of Lotus Development Corp.; biotech venture capitalist Robert Nelsen; and entrepreneur Matthew Mullenweg.
The company intends to use the funds to expand its operations to support the growth of its customer base, as well as initiate additional human clinical trials to evaluate the safety and efficacy of new products it plans to add to its offerings.
Led by Eric Marcotulli, CEO and co-founder, Elysium provides BASIS™, a daily product that supports metabolic health available to consumers exclusively through the website at $60 for a 30-day supply or $50 per month on a subscription plan.
FinSMEs
07/12/2016